Chemotherapy drug temozolomide under review for tough pituitary tumors

NCT ID NCT07695844

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at how well the chemotherapy drug temozolomide works for people with aggressive pituitary tumors or pituitary cancer that hasn't responded to standard treatments like surgery or radiation. Researchers are collecting data from medical records across multiple hospitals in Latin America to see how patients respond, how long the tumor is controlled, and whether certain tumor features can predict who benefits most. The goal is to fill a gap in knowledge, since most existing data comes from Europe and the United States.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
temozolomide (chemotherapy drug)
What this could lead to
If results are positive, this could confirm temozolomide as a reliable treatment option for aggressive pituitary tumors in Latin America.
What could go wrong
This is a retrospective study, not a controlled trial, so results may be less reliable. Temozolomide can cause side effects like nausea, fatigue, and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PITUITARY CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.